RIPA-56

• Description :

  RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H315, H319

• Target :

  RIP kinase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/RIPA-56.html

• Purity :

  99.94

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  CCC(C)(C)C(N(CC1=CC=CC=C1)O)=O

• Molecular Formula :

  C13H19NO2

• Molecular Weight :

  221.30

• Precautions :

  H302, H312, H315, H319

• References & Citations :

  [1]Ren Y, et al. Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-InteractingProtein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome. J Med Chem. 2017 Feb 9;60 (3) :972-986.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1956370-21-0]